BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 35479084)

  • 1. Crosstalk Between Metabolism and Immune Activity Reveals Four Subtypes With Therapeutic Implications in Clear Cell Renal Cell Carcinoma.
    Wang Y; Zheng XD; Zhu GQ; Li N; Zhou CW; Yang C; Zeng MS
    Front Immunol; 2022; 13():861328. PubMed ID: 35479084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a polyamine gene expression score for predicting prognosis and treatment response in clear cell renal cell carcinoma.
    Chen M; Nie Z; Huang D; Gao Y; Cao H; Zheng L; Zhang S
    Front Immunol; 2022; 13():1048204. PubMed ID: 36505496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPCS, a Novel Classifier System Based on Senescence Axis Regulators Reveals Tumor Microenvironment Heterogeneity and Guides Frontline Therapy for Clear Cell Renal Carcinoma.
    Jiang A; Liu Y; Zhu B; Fang Y; Qu L; Yang Q; Luo P; Cai C; Wang L
    Clin Genitourin Cancer; 2024 Apr; 22(2):497-513. PubMed ID: 38245436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the Role of Melatonin-Related Signatures in Tumor Immunity and the Prognosis of Clear Cell Renal Cell Carcinoma.
    Jiang A; Cai C; Yang Y; Cui Y; Liu W; Pang Q; Wu Z; Liu B; Qu L; Luo P; Wang A; Wang L
    Oxid Med Cell Longev; 2023; 2023():3077091. PubMed ID: 36825082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
    Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of immune subtypes to guide immunotherapy and targeted therapy in clear cell renal cell carcinoma.
    Xu C; Li Y; Su W; Wang Z; Ma Z; Zhou L; Zhou Y; Chen J; Jiang M; Liu M
    Aging (Albany NY); 2022 Sep; 14(17):6917-6935. PubMed ID: 36057262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive analysis of a tryptophan metabolism-related model in the prognostic prediction and immune status for clear cell renal carcinoma.
    Yao Q; Zhang X; Wang Y; Wang C; Wei C; Chen J; Chen D
    Eur J Med Res; 2024 Jan; 29(1):22. PubMed ID: 38183155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk of disulfidptosis-related subtypes identifying a prognostic signature to improve prognosis and immunotherapy responses of clear cell renal cell carcinoma patients.
    Ren L; Liu J; Lin Q; He T; Huang G; Wang W; Zhan X; He Y; Huang B; Mao X
    BMC Genomics; 2024 Apr; 25(1):413. PubMed ID: 38671348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive analysis of cellular senescence-related genes in the prognosis, tumor microenvironment, and immunotherapy/chemotherapy of clear cell renal cell carcinoma.
    Lu C; Wang Y; Nie L; Chen L; Li M; Qing H; Li S; Wu S; Wang Z
    Front Immunol; 2022; 13():934243. PubMed ID: 36189255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A New Signature That Predicts Progression-Free Survival of Clear Cell Renal Cell Carcinoma with Anti-PD-1 Therapy.
    Lin J; Cai Y; Ma Y; Pan J; Wang Z; Zhang J; Liu Y; Zhao Z
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and validation of an immune-related gene prognostic signature for clear cell renal carcinoma.
    Hua S; Xie Z; Zhang Y; Wu L; Shi F; Wang X; Xia S; Dong S; Jiang J
    Front Immunol; 2022; 13():869297. PubMed ID: 35936012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma.
    Jiang A; Wu X; Wang D; Wang A; Dong K; Liu B; Qu L; Luo P; Wang J; Tong Q; Wang L
    Front Immunol; 2022; 13():935595. PubMed ID: 35935986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular subtypes based on metabolic genes are potential biomarkers for predicting prognosis and immune responses of clear cell renal cell carcinoma.
    Wang Y; Ji H; Zhu B; Xing Q; Xie H
    Eur J Immunol; 2023 Jan; 53(1):e2250105. PubMed ID: 36367018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications.
    Wang Q; Hu J; Kang W; Wang J; Xiang Y; Fu M; Gao H; Huang Z
    Medicine (Baltimore); 2021 Mar; 100(11):e24949. PubMed ID: 33725966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deciphering the implications of mitophagy-related signatures in clinical outcomes and microenvironment heterogeneity of clear cell renal cell carcinoma.
    Xiang J; Liu W; Liu S; Wang T; Tang H; Yang J
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16015-16030. PubMed ID: 37689589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of Molecular Heterogeneity Associated With Tumor Microenvironment in Clear Cell Renal Cell Carcinoma to Aid Immunotherapy.
    Zhong W; Li Y; Yuan Y; Zhong H; Huang C; Huang J; Lin Y; Huang J
    Front Cell Dev Biol; 2021; 9():736540. PubMed ID: 34631713
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a claudin-low subtype in clear cell renal cell carcinoma with implications for the evaluation of clinical outcomes and treatment efficacy.
    Zhang C; Li Y; Qian J; Zhu Z; Huang C; He Z; Zhou L; Gong Y
    Front Immunol; 2022; 13():1020729. PubMed ID: 36479115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene set enrichment analysis identifies immune subtypes of kidney renal clear cell carcinoma with significantly different molecular and clinical properties.
    Chen Z; Cao W; Luo J; Abdelrahman Z; Lu Q; Wang H; Wang X
    Front Immunol; 2023; 14():1191365. PubMed ID: 37426638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.